What is ABGRAT Medical Intelligence?

ABGRAT is a global medical intelligence platform that analyzes breakthroughs from WHO, NIH, CDC, and NEJM using AI to deliver clinical insights to healthcare professionals.

How does ABGRAT analyze medical news?

ABGRAT uses deterministic medical logic combined with adaptive AI reasoning to process and validate medical articles, providing summaries, clinical significance, and risk assessments.

What medical specialties does ABGRAT cover?

ABGRAT covers Oncology, Cardiology, Neurology, Genetics, Medical AI, Infectious Diseases, Obstetrics, Surgery, Radiology, Public Health, Emergency Medicine, and more.

Is ABGRAT a substitute for professional medical advice?

No. ABGRAT provides AI-generated clinical insights for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Home Medical NewsFDA Approves Weekly Basal Insulin for Adults With Type 2 Diabetes

General Medicinegeneral

FDA Approves Weekly Basal Insulin for Adults With Type 2 Diabetes

JAMA – Journal of the American Medical AssociationMay 12, 20263 min readReliability 98%

Written & Analyzed by

Abgrat Medical Intelligence Team

Published: May 12, 2026

Medically Reviewed by

Abgrat Medical Review Board

Board-certified physicians and AI researchers

Source Reliability: 98%Last Reviewed: May 2026

Cross-referenced with trusted medical databases:

WHO GuidelinesNIH PubMedCDC Clinical ResourcesNEJM Evidence

⚕️ This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

The US Food and Drug Administration (FDA) approved insulin icodec-abae, marketed as Awiqli, making it the first once-weekly basal insulin treatment option for adults with type 2 diabetes.